文献速递外周动脉疾病

重症肢体缺血下肢旁路术与腔内介入比较:旁路术降低主要不良肢体事件且心脏风险相当

Lower extremity bypass for critical limb ischemia decreases major adverse limb events with equivalent cardiac risk compared with endovascular intervention.
PubMed 文献 · J Vasc Surg · 2017-06-24

该研究基于NSQIP血管靶向文件(2011-2014)纳入8066例重症肢体缺血患者,经倾向性匹配后每组1924例。结论支持LEB在CLI血运重建中的有效性和优先地位。

要点

  • 单段大隐静脉旁路、抗血小板及他汀治疗为MALE保护因素。

核心结论

  • 在倾向匹配的国家队列中,LEB相比IEI预测更低的30天风险校正MALE率。
  • 尽管开放手术固有风险更高,两组30天MACE率无差异。
  • 研究支持LEB在CLI血运重建中的有效性和优先地位。

研究设计与样本

  • 基于NSQIP血管靶向文件(2011-2014)的倾向性评分匹配、国家队列研究。
  • 共识别13294例LEB和IEI,其中8066例为CLI。
  • 倾向匹配后纳入3848例(每组1924例),组间术前变量无差异(所有P>.05)。

主要发现

  • 30天MALE率LEB组9.2% vs IEI组12.2%(P=.003)。
  • 30天MACE率LEB组4.9% vs IEI组3.7%(P=.07),无显著差异。
  • MALE独立预测因素:单段大隐静脉旁路vs IEI(OR 0.7,95%CI 0.54-0.92,P=.01)、替代管道旁路vs IEI(OR 0.7,95%CI 0.56-0.98,P=.04)、抗血小板治疗(OR 0.8,95%CI 0.58-1.00,P=.049)、他汀治疗(OR 0.8,95%CI 0.62-0.99,P=.04)为保护因素;膝下介入(OR 1.4,95%CI 1.09-1.72,P=.01)和同段既往旁路史(OR 1.8,95%CI 1.41-2.41,P<.0001)为预测因素。
  • MACE独立预测因素:年龄(OR 1.02,95%CI 1.01-1.04,P=.01)、激素使用(OR 1.8,95%CI 1.08-2.99,P=.03)、充血性心力衰竭(OR 1.7,95%CI 1.00-1.96,P=.02)、β受体阻滞剂使用(OR 1.6,95%CI 1.09-1.43,P=.01)、透析(OR 2.3,95%CI 1.55-3.45,P<.0001)、完全依赖功能状态(OR 3.1,95%CI 1.25-7.58,P=.02)、LEB使用不理想管道vs IEI(OR 1.6,95%CI 1.08-2.36,P=.02)。

临床怎么用

  • 对于CLI患者,LEB可考虑作为血运重建的优先选择以降低30天MALE风险。
  • 围术期应关注抗血小板和他汀治疗以降低MALE风险。
  • 合并透析、心衰、激素使用等高危因素者需警惕MACE。

局限性

  • 回顾性队列设计,尽管倾向匹配仍可能存在未测量混杂。
  • 仅报告30天结局,缺乏长期随访数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Lower extremity bypass (LEB) has traditionally been the "gold standard" in the treatment of critical limb ischemia (CLI). Infrainguinal endovascular intervention (IEI) has become more commonly performed than LEB, but comparative outcomes are limited. We sought to compare rates of major adverse limb events (MALEs) and major adverse cardiovascular events (MACEs) after LEB and IEI in a propensity score-matched, national cohort of patients with CLI. METHODS: The National Surgical Quality Improvement Program (NSQIP) vascular targeted files (2011-2014) for LEB and IEI were merged. CLI patients were identified by ischemic rest pain or tissue loss. Patients were matched on a 1:1 basis for propensity to undergo LEB or IEI. Primary outcomes were 30-day MALEs and MACEs. Within the propensity-matched cohort, multivariate logistic regression was used to identify independent predictors of MALEs and MACEs. RESULTS: A total of 13,294 LEBs and IEIs were identified, with 8066 cases performed for CLI. Propensity matching identified 3848 cases (1924 per group). There were no differences in preoperative variables between the propensity-matched LEB and IEI groups (all P > .05). At 30 days, rates of MALEs were significantly lower in the LEB group (9.2% LEB vs IEI 12.2%; P = .003). On multivariate logistic regression, bypass with single-segment saphenous vein vs IEI (odds ratio [OR], 0.7; 95% confidence interval [CI], 0.54-0.92; P = .01), bypass with alternative conduit (prosthetic, spliced vein, or composite) vs IEI (OR, 0.7; 95% CI, 0.56-0.98; P = .04), antiplatelet therapy (OR, 0.8; 95% CI, 0.58-1.00; P = .049), and statin therapy (OR, 0.8; 95% CI, 0.62-0.99; P = .04) were protective against MALEs, whereas infrageniculate intervention (OR, 1.4; 95% CI, 1.09-1.72; P = .01) and a history of prior bypass of the same arterial segment (OR, 1.8; 95% CI, 1.41-2.41; P <. 0001) were predictive. Rates of 30-day MACEs were not significantly different (4.9% LEB vs 3.7% IEI; P = .07) between the groups. Independent predictors of MACEs included age (OR, 1.02; 95% CI, 1.01-1.04; P = .01), steroid use (OR, 1.8; 95% CI, 1.08-2.99; P = .03), congestive heart failure (OR, 1.7; 95% CI, 1.00-1.96; P = .02), beta blocker use (OR, 1.6; 95% CI, 1.09-1.43; P = .01), dialysis (OR, 2.3; 95% CI, 1.55-3.45; P < .0001), totally dependent functional status (OR, 3.1; 95% CI, 1.25-7.58; P = .02), and suboptimal conduit for LEB compared with IEI (OR, 1.6; 95% CI, 1.08-2.36; P = .02). CONCLUSIONS: Within this large, propensity-matched, national cohort, LEB predicted lower risk-adjusted 30-day MALE rate compared with IEI. Furthermore, there was no difference in 30-day MACE rate between the groups despite higher inherent risk with open surgical procedures. Therefore, this study supports the effectiveness and primacy of LEB for revascularization in CLI.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Mehaffey JH, Hawkins RB, Fashandi A, et al. Lower extremity bypass for critical limb ischemia decreases major adverse limb events with equivalent cardiac risk compared with endovascular intervention. J Vasc Surg. 2017. PMID: 28655549. doi:10.1016/j.jvs.2017.04.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。